Sam Altman invested $180 million into a company trying to delay death | MIT Technology Review
technologyreview.com · 3,188 words · saved by 1 readers
Can anti-aging breakthroughs add 10 healthy years to the human lifespan? The CEO of OpenAI is paying to find out.
Sam Altman invested $180 million into a company trying to delay death | MIT Technology Review Skip to Content When a startup called Retro Biosciences eased out of stealth mode in mid-2022, it announced it had secured $180 million to bankroll an audacious mission: to add 10 years to the average human life span . It had set up its headquarters in a raw warehouse space near San Francisco just the year before, bolting shipping containers to the concrete floor to quickly make lab space for the scientists who had been enticed to join the company. Retro said that it would “prize speed” and “tighten f
related reading
- Bottlenecks of Aging - Amaranth Foundationamaranth.foundation
- Meet Altos Labs, Silicon Valley's latest wild bet on living forever | MIT Technology Reviewtechnologyreview.com
- Sam Altman’s Manifest Destiny | The New Yorkernewyorker.com
- Sam Altman May Control Our Future—Can He Be Trusted? | The New Yorkernewyorker.com
- Amaranth Foundation - Longevity and Neuroscienceamaranth.foundation
- David Senra: Sam Altman on Building OpenAI & Betting on the Impossibledavidsenra.com
- Anti-Aging: State of the Art — LessWronglesswrong.com
- How to Live Forever and Get Rich Doing It | The New Yorkernewyorker.com
- Why Don’t Billionaires Invest In Longevity?nfx.com
- My Plan to Slow Down Aging - Richard Hanania's Newsletterrichardhanania.com
- Sam Altman - Wikipediaen.wikipedia.org
- Blake Byers | Build and Investblakebyers.com